Chronic Low Back Pain (CLBP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
CLBP Marketed and Pipeline Drugs Report Overview
Chronic low back pain (CLBP) is defined as pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain (BP) has been treated. It represents the second-leading cause of disability worldwide and is a major health and economic problem. CLBP is a complex disease with high heterogeneity and is increasingly dubbed a mixed pain syndrome with neuropathic and injurious components. CLBP develops in roughly 5% to 10% of low back pain cases and has a significant impact on functional capacity and occupational activities.
The Chronic Low Back Pain (CLBP) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for CLBP. The report also analyzes the clinical and commercial landscapes of CLBP, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Segments Covered in the Report
CLBP Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Receptor Antagonist
- Receptor Agonist
- Transporter Inhibitor
- Ion Channel Blocker
CLBP Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Topical
- Suppository
- Injection
- Inhalational
CLBP Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecules
- Biologic
CLBP Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Inhibitor
- Receptor Antagonist
- Ion Channel Blocker
- Transporter Inhibitor
- Receptor Inhibitor
CLBP Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Topical
- Oral
- Injection
CLBP Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
- Oligonucleotide
Scope
GlobalData’s CLBP Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CLBP market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CLBP market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for CLBP-marketed drugs?
The leading MoA for CLBP-marketed drugs is Enzyme Inhibitor.
-
Which is the leading RoA for CLBP-marketed drugs?
Oral is the leading route of administration for CLBP-marketed drugs.
-
Who are the top sponsors for the CLBP marketed and pipeline drugs market?
A few of the top sponsors in the CLBP marketed and pipeline drugs market are Pfizer, Lilly, Tabriz University of Medical Sciences, Shionogi & Co Ltd, and John Hopkins University among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Low Back Pain reports